 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

23ME-01473, antibody targeting ULBP6: Data will be presented on the discovery and biology of ULBP6, and the potential to restore natural killer and T cell-mediated anti-tumor immunity by targeting...

23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024

The latest update is out from 23andMe Holding (ME). Kathy Hibbs has announced her retirement as Chief Administrative Officer and Corporate Secretar...

23andMe CAO Kathy Hibbs Retires, Guy Chayoun Steps In

Looking Into 23andMe Holding's Recent Short Interest

23andMe Holding Co. (NASDAQ:ME  Get Free Report) insider Kathy L. Hibbs sold 38,548 shares of the firms stock in a transaction on Thursday, March 21st. The shares were sold at an...

Kathy L. Hibbs Sells 38,548 Shares of 23andMe Holding Co. (NASDAQ:ME) Stock

23ME-01473 ('1473) seeks to restore anti-tumor immunity through NK and T cells by blocking the immunosuppressive effects of soluble ULBP6 '1473 also induces Fc receptor-mediated killing of...

23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6

Built upon peer-reviewed published science, the Historical Matches feature weaves customers' ancestral connections into the story of human history and migrationSOUTH SAN FRANCISCO, Calif., March 19...

23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago

23andMe customers can now gain deeper insight into their likelihood of developing breast, colorectal, and prostate cancer through new reports based on polygenic risk scores (PRS) developed by...

23andMe Launches New Genetic Reports on Common Forms of Cancer

23andMe to give an oral presentation on the genetic signature of ULBP6, the target of 23ME-01473, along with poster presentations of the biology of ULBP6 and mechanism of 23ME-01473, and new...

23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024

Wittenberg Investment Management Inc. grew its holdings in shares of 23andMe Holding Co. (NASDAQ:ME  Free Report) by 88.8% in the 3rd quarter, according to the company in its most recent 13F...

23andMe Holding Co. (NASDAQ:ME) Shares Purchased by Wittenberg Investment Management Inc.

Announced new non-exclusive data license with GSK, introduced 23andMe Total Health , and received FDA clearance for IND on novel, dual-mechanism immuno-oncology asset 23ME-1473SOUTH SAN FRANCISCO...

23andMe Reports Third Quarter Fiscal 2024 Financial Results

23andMe Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. It operates through the Consumer and Research Services, and Therapeutics segments. The Consumer and Research Services segment consists of Personal Genome Service, Telehealth Business, and Research Services. The Therapeutics segment focuses on the genetic insights of genetic and phenotypic information. The company was founded by Anne E. Wojcickiin 2006 and is headquartered in South San Francisco, CA.

Volume (M)	17.23M
52-Wk High	$2.21
52-Wk Low	$0.35

ME 23andMe Holding Co - Ordinary Shares - Class A

About

Feed

News

Sentiment

Earnings

Fundamentals